

MRI whole gray matter brain volume: Percentage change from Baseline by visit
ITT population

	Placebo to Natalizumab 300 mg	Natalizumab 300 mg	p-value (a)
Percentage change from Baseline to Week 156			
n	149	170	
Mean	-1.566	-1.514	0.5034
SD	0.9303	0.8969	

(a)p-value for comparison between the active and placebo groups at Week 156 is based on ANCOVA model, adjusted for 5.5 or >=6) and baseline whole gray matter brain volume.

natalizumab subjects had a baseline after 6 months of treatment and the placebo-to-natalizumab group had a baseline of initiation of treatment